The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health
NCT ID: NCT01709825
Last Updated: 2015-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
583 participants
INTERVENTIONAL
2012-09-30
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Probiotics on Stress-associated Gastrointestinal Function in University Students
NCT03056846
Effect of Probiotic on the Gut Microbiota of Healthy Volunteers
NCT06103253
Probiotics (L. Gasseri, B. Bifidum, B. Longum) on Immune and Intestinal Health in Healthy Older Adults
NCT01662206
Probiotics, Immunity, Stress, and QofL
NCT05063305
The Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation
NCT01879098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will provide saliva and stool samples (for the sub-group)during the pre-baseline week and during the week of final exams at approximately week 4. At the randomization visit, height, weight and age will be obtained. Participants will be stratified based on body mass index and randomized via sealed envelopes to one of four groups: Lactobacillus helveticus, Bifidobacterium longum ssp. Infantis, Bifidobacterium bifidum or the placebo (n=145/group). Participants will take the study provided capsule of probiotic or placebo daily for 6 weeks. Participants will receive daily questionnaires via email throughout the prebaseline week and the 6-week intervention. Daily questionnaires will ask about intake of the supplement, cold symptoms, and general health (i.e., new medications, doctor visits). Throughout the study, participants will also be asked to complete weekly questionnaires (inquiring about gastrointestinal symptoms and physical activity) and Quality of Life Questionnaires (administered during pre-baseline, final exam week and week 6 of the study).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sugar Pill
Sugar Pill will be taken as a capsule once daily for 6 weeks.
Sugar Pill
Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
Probiotic- Bifidobacterium bifidum
Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
Probiotic- Bifidobacterium Bifidum
Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
Probiotic- Lactobacillus helveticus
Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
Probiotic- Lactobacillus helveticus
Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
Probiotic- Bifidobacterium longum ss. Infantis R0033
Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
Probiotic- Bifidobacterium longum ss. Infantis R0033
Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic- Bifidobacterium Bifidum
Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
Sugar Pill
Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
Probiotic- Lactobacillus helveticus
Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
Probiotic- Bifidobacterium longum ss. Infantis R0033
Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* be 18 years of age or older.
* be a healthy full-time undergraduate at the University of Florida.
* be willing to complete daily questionnaires form via computer.
* be willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics and fiber supplements, probiotics, echinacea, fish oil, vitamin E \>400% of the RDA or \>60 mg/day).
* be willing to take the probiotic capsule daily of 6 weeks.
* have had at least one cold in the last 12 months.
* have at least 1 final during the scheduled exam week.
* have daily access to the Internet.
Exclusion Criteria
* be a current smoker.
* have chronic allergies involving the upper respiratory tract.
* have had immunosuppressive illness or treatment within the last year.
* have received antibiotic therapy in the past two months.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lallemand Human Nutrition
UNKNOWN
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bobbi Langkamp-Henken, PhD, RD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Wendy Dahl, PhD, RD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Langkamp-Henken B, Rowe CC, Ford AL, Christman MC, Nieves C Jr, Khouri L, Specht GJ, Girard SA, Spaiser SJ, Dahl WJ. Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015 Feb 14;113(3):426-34. doi: 10.1017/S0007114514003997. Epub 2015 Jan 21.
Culpepper T, Christman MC, Nieves C Jr, Specht GJ, Rowe CC, Spaiser SJ, Ford AL, Dahl WJ, Girard SA, Langkamp-Henken B. Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress: a secondary analysis of a randomised trial. Benef Microbes. 2016 Jun;7(3):327-36. doi: 10.3920/BM2015.0156. Epub 2016 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
403-2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.